Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Cellectis S.A.✕ ALCLS.PA |
|---|---|
| Profile | |
| Country | 🇫🇷 France |
| Sector | Healthcare |
| Industry | Biotechnology |
| Founded | — |
| Size | |
| Revenue | $73 M |
| Net income | $-68 M |
| Profitability | |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Cellectis S.A. |
|---|---|
| 2025 | $73 MSEC |
| 2024 | $42 MSEC |
| 2023 | $1 MSEC |
| 2022 | $19 MSEC |
| 2021 | $30 MSEC |
| 2020 | $51 MSEC |
| 2019 | $15 MSEC |
| 2018 | $13 MSEC |
| 2017 | $25 MSEC |
| 2016 | $45 MSEC |
| 2015 | $56 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| Operating margin | -45.4% |
|---|
| Net margin | -92.7% |
|---|
| Return on equity | -65.3% |
|---|
| Growth | |
|---|---|
| Revenue growth | 75.8% |
| Financial strength | |
|---|---|
| Interest cover | -0.7× |
| Cash | |
|---|---|
| Free cash flow margin | -57.2% |
| Altman Z-score zone | — |
|---|
| Data as of | Market cap Jan 2024; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.